Operator: Good morning and thank you for standing by. Welcome to the AbbVie First Quarter 2013 Earnings Conference Call. All participants will be able to listen-only until the question-and-answer portion of this call. Should you become disconnected throughout this conference call, please dial 1-877-918-6633 and reference the AbbVie call.
This call is being recorded by AbbVie. With the exception of any participants' questions asked during the question-and-answer session the entire call, including the question-and-answer session is material copyrighted by AbbVie. It cannot be recorded or rebroadcast with AbbVie's expressed written permission.
I would now like to introduce Mr. Larry Peepo, Vice President of Investor Relations.
Larry Peepo - VP of Investor Relations: Good morning and thanks for joining us. Also on the call with me today is Rick Gonzalez, Chairman of the Board and Chief Executive Officer and Bill Chase, Executive Vice President of Finance and Chief Financial Officer. Joining us for the question and answer portion of the call are Laura Schumacher, Executive Vice President of Business Development, External Affairs and General Counsel and John Leonard, Senior Vice President and Chief Scientific Officer.
Today, Rick will discuss AbbVie's results from the first quarter as well as highlights from our commercial portfolio and pipeline. Following Rick's comments, Bill will give a more detailed review of the quarter and then provide an overview of our outlook for 2013 and the second quarter. Following our comments, we'll take your questions.
Before we get started, some statements may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words believe, expect, anticipate, project, and similar expressions among others generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action and changes to laws and regulations applicable to our industry.
Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, Risk Factors in our 2012 Annual Report on Form 10-K, which has been filed with the securities and exchange commission. AbbVie undertakes no obligations to release publicly any revisions to forward-looking statements as a result of subsequent events or developments except as required by law.
On today's conference call, as in the past, non-GAAP financial measures will be used to help our investors understand AbbVie's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website at www.abbvieinvestor.com.